PUBLISHER: TechSci Research | PRODUCT CODE: 1714375
PUBLISHER: TechSci Research | PRODUCT CODE: 1714375
Biosimilar Monoclonal Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region and Competition, 2020-2030F
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The Global Biosimilar Monoclonal Antibodies Market was valued at USD 5.47 billion in 2024 and is projected to reach USD 10.83 billion by 2030, expanding at a CAGR of 12.03%. Biosimilar monoclonal antibodies (mAbs) represent a transformative segment in the biopharmaceutical industry due to their cost-effective nature and comparable efficacy to originator biologics. As biologic drugs become increasingly essential in treating conditions like cancer, autoimmune, and inflammatory diseases, biosimilar mAbs offer a promising alternative, especially given their affordability and accessibility. Though biosimilars are not identical to reference biologics, they are engineered to closely match in safety, efficacy, and quality. Their development through advanced recombinant DNA technology in living cells enables broader patient access and helps mitigate healthcare expenditures. As healthcare systems globally grapple with high biologic costs, biosimilar mAbs are gaining traction for their potential to alleviate economic burdens while maintaining therapeutic outcomes.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 5.47 Billion |
| Market Size 2030 | USD 10.83 Billion |
| CAGR 2025-2030 | 12.03% |
| Fastest Growing Segment | Oncology |
| Largest Market | North America |
Key Market Drivers
Rising Cancer and Autoimmune Disorders
The global upsurge in cancer and autoimmune diseases has led to a growing demand for effective and affordable therapies, thereby propelling the biosimilar monoclonal antibodies (mAbs) market. Cancer, characterized by abnormal cell growth, continues to be a major cause of mortality, with the European Union reporting a 2.3% rise in new cases and a 2.4% increase in cancer-related deaths in 2022 compared to 2020. Similarly, autoimmune diseases are becoming more prevalent, heightening the necessity for targeted and cost-efficient treatments. Biosimilar mAbs have emerged as a valuable solution by providing therapeutic efficacy comparable to reference biologics at reduced costs. This market segment is increasingly crucial in balancing patient needs and healthcare affordability, driving its expansion in the global pharmaceutical landscape.
Key Market Challenges
Manufacturing Complexity
The production of biosimilar monoclonal antibodies (mAbs) is fraught with complexity due to their biological origins. These therapies are derived from living cells, introducing inherent variability in expression systems, cell lines, and culture conditions. Such variability can lead to slight differences between biosimilars and their reference biologics, complicating efforts to maintain consistent quality and biological performance. Ensuring equivalence in physicochemical properties, biological activity, and immunogenicity requires robust quality control and advanced analytical tools. Minor changes in the manufacturing process can significantly affect clinical outcomes, presenting a regulatory and developmental hurdle. This complexity results in higher development costs and prolonged timelines, emphasizing the need for substantial investments to achieve regulatory compliance and maintain product consistency.
Key Market Trends
Technological Advancements
Technological innovation is driving the evolution of biosimilar monoclonal antibodies (mAbs), transforming them into precision therapeutic tools. Advances in biotechnology and research have facilitated the development of biosimilars that closely replicate the safety and efficacy of originator biologics. These breakthroughs support the rise of personalized medicine by enabling therapies tailored to individual genetic and disease profiles. Concurrently, innovations in bioprocessing, such as enhanced cell culture methods and purification techniques, have significantly improved production efficiency and product quality. These developments not only reduce manufacturing costs but also ensure better patient outcomes. As a result, biosimilar mAbs are increasingly integrated into treatment regimens, bolstered by their improved accessibility, affordability, and alignment with modern medical strategies.
Key Market Players * Abbott
- Pfizer
- Novartis AG
- AbbVie, Inc.
- Coherus BioSciences
- Biocon Limited
- Allergan plc.
- Accord Healthcare limited.
- Amgen inc.
- Dr. Reddy's Laboratory
Report Scope: In this report, the Global Biosimilar Monoclonal Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Biosimilar Monoclonal Antibodies Market, By Product:
- Infliximab
- Rituximab
- Abciximab
- Trastuzumab
- Adalimumab
- Bevacizumab
- Others
Biosimilar Monoclonal Antibodies Market, By Application:
- Oncology
- Chronic & Autoimmune Diseases
- Others
Biosimilar Monoclonal Antibodies Market, By Region:
- North America
- Asia-Pacific
- Europe
- Middle East & Africa
- South America
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Biosimilar Monoclonal Antibodies Market.
Available Customizations:
Global Biosimilar Monoclonal Antibodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global Biosimilar Monoclonal Antibodies Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Product (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab, Others)
- 5.2.2. By Application (Oncology, Chronic & Autoimmune Diseases, Others)
- 5.2.3. By Company (2024)
- 5.2.4. By Region
- 5.3. Market Map
6. North America Biosimilar Monoclonal Antibodies Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Application
- 6.2.3. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Biosimilar Monoclonal Antibodies Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product
- 6.3.1.2.2. By Application
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Mexico Biosimilar Monoclonal Antibodies Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product
- 6.3.2.2.2. By Application
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Canada Biosimilar Monoclonal Antibodies Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product
- 6.3.3.2.2. By Application
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States Biosimilar Monoclonal Antibodies Market Outlook
7. Europe Biosimilar Monoclonal Antibodies Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Application
- 7.2.3. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Biosimilar Monoclonal Antibodies Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product
- 7.3.1.2.2. By Application
- 7.3.1.1. Market Size & Forecast
- 7.3.2. Germany Biosimilar Monoclonal Antibodies Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product
- 7.3.2.2.2. By Application
- 7.3.2.1. Market Size & Forecast
- 7.3.3. United Kingdom Biosimilar Monoclonal Antibodies Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product
- 7.3.3.2.2. By Application
- 7.3.3.1. Market Size & Forecast
- 7.3.4. Italy Biosimilar Monoclonal Antibodies Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product
- 7.3.4.2.2. By Application
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain Biosimilar Monoclonal Antibodies Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Product
- 7.3.5.2.2. By Application
- 7.3.5.1. Market Size & Forecast
- 7.3.1. France Biosimilar Monoclonal Antibodies Market Outlook
8. Asia-Pacific Biosimilar Monoclonal Antibodies Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Application
- 8.2.3. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Biosimilar Monoclonal Antibodies Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product
- 8.3.1.2.2. By Application
- 8.3.1.1. Market Size & Forecast
- 8.3.2. India Biosimilar Monoclonal Antibodies Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product
- 8.3.2.2.2. By Application
- 8.3.2.1. Market Size & Forecast
- 8.3.3. South Korea Biosimilar Monoclonal Antibodies Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product
- 8.3.3.2.2. By Application
- 8.3.3.1. Market Size & Forecast
- 8.3.4. Japan Biosimilar Monoclonal Antibodies Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Product
- 8.3.4.2.2. By Application
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Australia Biosimilar Monoclonal Antibodies Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Product
- 8.3.5.2.2. By Application
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China Biosimilar Monoclonal Antibodies Market Outlook
9. South America Biosimilar Monoclonal Antibodies Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Application
- 9.2.3. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Biosimilar Monoclonal Antibodies Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product
- 9.3.1.2.2. By Application
- 9.3.1.1. Market Size & Forecast
- 9.3.2. Argentina Biosimilar Monoclonal Antibodies Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product
- 9.3.2.2.2. By Application
- 9.3.2.1. Market Size & Forecast
- 9.3.3. Colombia Biosimilar Monoclonal Antibodies Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product
- 9.3.3.2.2. By Application
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Brazil Biosimilar Monoclonal Antibodies Market Outlook
10. Middle East and Africa Biosimilar Monoclonal Antibodies Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Application
- 10.2.3. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Biosimilar Monoclonal Antibodies Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product
- 10.3.1.2.2. By Application
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Saudi Arabia Biosimilar Monoclonal Antibodies Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product
- 10.3.2.2.2. By Application
- 10.3.2.1. Market Size & Forecast
- 10.3.3. UAE Biosimilar Monoclonal Antibodies Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product
- 10.3.3.2.2. By Application
- 10.3.3.1. Market Size & Forecast
- 10.3.1. South Africa Biosimilar Monoclonal Antibodies Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Porters Five Forces Analysis
- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Products
14. Competitive Landscape
- 14.1. Abbott
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
- 14.2. Pfizer
- 14.3. Novartis AG
- 14.4. AbbVie, Inc.
- 14.5. Coherus BioSciences
- 14.6. Biocon Limited
- 14.7. Allergan plc.
- 14.8. Accord Healthcare limited.
- 14.9. Amgen inc.
- 14.10. Dr. Reddy's Laboratory
15. Strategic Recommendations
16. About Us & Disclaimer
